



Guideline-directed Medical Therapy Use in Canadian Patients Suffering from Heart Failure with Reduced Ejection Fraction (HFrEF): The HF-iDOC Program

FRIDAY, MAY 27, 2022

2:55-3:15 pm EDT



ANIQUE DUCHARME

MD, MSc, FRCP, FHFS(h)
President, Canadian Heart Failure Society
Professor of Medicine, Université de Montréal
Director, Heart Failure Clinic
Montreal Heart Institute, Research Center
Montreal, QC



SHAUN GOODMAN

MD, MSc, FRCPC, FACC, FAHA, FESC, FCCS
Associate Head, Division of Cardiology
Professor, Department of Medicine, University of Toronto
Consultant, Canadian Heart Research Centre
Co-Director, Canadian VIGOUR Centre
Adjunct Professor, Department of Medicine,
University of Alberta
Toronto, ON

HF-iDOC (Heart Failure iDentification and Optimization in the Community) is an initiative to educate, encourage and motivate community-based cardiologists to ensure patients living with heart failure with reduced ejection fraction (HFrEF) are optimized on foundational therapy as recommended in the 2021 CCS/CHFS Guidelines Update on HFrEF Management. Currently, it is estimated that less than 10% of Canadians living with HFrEF are receiving the four drugs that constitute foundational therapy (ARNI, MRA, betablocker, SGLT2i) to improve their outcomes, by extending survival and reducing HF hospitalizations.

The opportunity for quality improvement (QI) is considerable and is the focus of this initiative. Join Dr. Anique Ducharme and Dr. Shaun Goodman to review the data available to date from HF-iDOC.

This Corridor Consult is available **LIVE** for the **VIRTUAL** audience and **ON-DEMAND** for all delegates after the congress

Visit cardiovasupdate.ca to register for the hybrid congress